INVO Fertility (NASDAQ:IVF) Releases Earnings Results

INVO Fertility (NASDAQ:IVF) posted its earnings results on Monday. The company reported ($3.38) earnings per share (EPS) for the quarter, FiscalAI reports. The firm had revenue of $2.02 million during the quarter.

INVO Fertility Price Performance

NASDAQ:IVF opened at $1.39 on Tuesday. The company has a quick ratio of 0.25, a current ratio of 0.27 and a debt-to-equity ratio of 0.15. The business’s 50-day moving average price is $1.74 and its 200 day moving average price is $3.81. INVO Fertility has a 52-week low of $1.26 and a 52-week high of $183.60. The firm has a market cap of $2.49 million, a P/E ratio of -0.00 and a beta of 2.33.

Wall Street Analyst Weigh In

IVF has been the topic of a number of recent analyst reports. Weiss Ratings raised INVO Fertility from a “sell (e)” rating to a “sell (e+)” rating in a research report on Wednesday, May 6th. Wall Street Zen raised shares of INVO Fertility from a “sell” rating to a “hold” rating in a research report on Saturday, March 7th. One equities research analyst has rated the stock with a Strong Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $20.00.

Institutional Trading of INVO Fertility

An institutional investor recently bought a new stake in INVO Fertility stock. Citadel Advisors LLC acquired a new stake in shares of INVO Fertility, Inc (NASDAQ:IVF) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 66,849 shares of the company’s stock, valued at approximately $51,000. Citadel Advisors LLC owned about 1.19% of INVO Fertility as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 12.02% of the company’s stock.

INVO Fertility Company Profile

INVO Fertility (NASDAQ:IVF) is a medical technology company focused on advancing assisted reproductive treatments through innovative in-vivo incubation solutions. The company develops and commercializes devices designed to facilitate fertilization and early embryo development inside a patient’s body, offering an alternative to conventional laboratory-based in vitro fertilization (IVF) techniques.

The company’s flagship product, the INVOcell device, is a single-use, intravaginal incubator that holds a controlled microenvironment for egg and sperm co-incubation.